NJ Bio, Inc. ads

NJ Bio, Inc. is proud to announce a new collaboration with Ajinomoto Bio-Pharma Services to integrate their AJICAP™ site-specific conjugation platform into our discovery and early development workflows. Through this partnership, our clients will gain access to a proven, precision conjugation technology from the very start of their programs, combined with NJ Bio's end-to-end early-stage development and manufacturing capabilities. This integrated approach is designed to reduce developmental risks and accelerates the path to a validated candidate. We’re grateful to the Aji Bio-Pharma team for this collaboration and look forward to delivering impactful solutions together for our clients. Read the full press release here: https://lnkd.in/eu3_ZFpx #ADCs #SiteSpecificConjugation #Biopharma #Manufacturing

Choosing the right conjugation approach isn’t just a technical decision - it directly impacts timelines, developmental risk, and long-term success. Platform choice, scalability, and reproducibility all play a critical role in how smoothly an #ADC or #AOC program progresses. Through our collaboration with Ajinomoto Bio-Pharma Services, NJ Bio brings AJICAP™ technology directly to our clients, enabling the integration of a proven conjugation approach earlier in development and supporting more confident decision-making from the start. Get in touch to learn how we can support your program https://njbio.com/contact/ #Bioconjugation #AntibodyOligonucleotideConjugates #AntibodyDrugConjugates #Collaboration

NJ Bio is heading to San Francisco, January 12–15, for the 44th J.P. Morgan Healthcare Conference. If you’re working to move an #ADC from early design into clinical development, need timely and cost-effective support to reach critical milestones, or are exploring new chemistry approaches to improve safety and efficacy, our team would love to connect. With years of experience in chemistry and bioconjugation, we bring the scientific depth and practical insight needed to help de-risk development and accelerate progress. If you’ll be at #JPM2026, we’d welcome the opportunity to connect.

NJ Bio offers a comprehensive drug discovery and development service platform, supporting programs from design through IND-enabling studies. We help bridge the critical gap between preclinical and clinical research through robust in vitro and in vivo translational studies, enabling our clients to de-risk programs early and build stronger value propositions for investors. Meet us at #JPM2026 to learn how we can accelerate your drug discovery program. Schedule a meeting with our team by reaching out directly or through BIO Partnering. #DrugDiscovery #DrugDevelopment #IND #TranslationalResearch

NJ Bio is excited to kick off 2026 at the 44th J.P. Morgan Healthcare Conference, taking place January 12 -15 in San Francisco. Why meet with us? ✔️You need to right expertise to advance your ADC from design to the clinic. ✔️You need timely, cost-effective support to reach critical milestones. ✔️You’re looking to overcome current ADC limitations and improve safety and efficacy through novel and tailored chemistry approaches. ✔️You want to collaborate with a highly experienced ADC team that has supported 200+ programs and advanced many to the clinic. If you’ll be attending #JPM2026 and would like to connect, please reach out or schedule some time through BIO Partnering #JPMWeek2026. Our team Julien Dugal-Tessier, Naresh Jain and Brian M. would be happy to meet you! See you in San Francisco!

Around 90% of drugs entering Phase I human trials fail and one of the biggest contributors to this failure is the lack of predictive preclinical models. Choosing the right in vivo model early can prevent costly clinical failures later, saving years of R&D time and millions in development costs. At NJ Bio, we have built a comprehensive translational research platform that closes this preclinical-to-clinical gap by offering - Large libraries of validated CDX & PDX models, Syngeneic & immuno-oncology models, Humanized mouse models, Robust in vitro assays & 3D tumor systems, PK/PD studies and tumor exposure assessments, Bioanalytical (LC-MS/MS) support 🔸 All under one roof 🔸 This integrated approach allows us to generate more clinically relevant data and provides drug developers with a clearer line of sight from discovery to IND and clinical success. If you are working in oncology, biologics, ADCs, or IO, developing a translational strategy early may be the single most impactful decision you make. Learn more: https://lnkd.in/dpdd8apj #TranslationalResearch #invivostudies #invitrostudies #immunooncology #animalmodels #ADC